COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
1 - 29 . (canceled)
30 . A method for treating multiple myeloma in a human patient, the method comprising orally administering once daily GDC-0199 to the patient in escalating doses, wherein a starting dose of the escalating doses is less than 300 mg per day and an ending dose of the escalating doses is 300 mg per day.
31 . The method of claim 30 , wherein the method comprises administering the once daily dose of GDC-0199 in multiple dosing cycles, and each dosing cycle of the multiple dosing cycles is 28 days.
32 . The method of claim 30 , wherein the GDC-0199 is administered in combination with an effective amount of obinutuzumab, and the effective amount of the obinutuzumab is 1000 mg.
33 . The method of claim 32 , wherein the effective amount of the obinutuzumab is administered to the patient in combination with the GDC-0199 in multiple dosing cycles, and the effective amount of the obinutuzumab is administered once in each dosing cycle for 6 to 7 dosing cycles of the multiple dosing cycles.
34 . The method of claim 30 , wherein the GDC-0199 is administered in combination with an effective amount of dexamethasone.
35 . The method of claim 33 , wherein each dosing cycle of the multiple dosing cycles is 28 days.
36 . The method of claim 30 , wherein the multiple myeloma is refractory multiple myeloma.
37 . The method of claim 30 , wherein the method is continued until disease progression.
38 . A method for treating multiple myeloma in a human patient, the method comprising orally administering a once daily dose of GDC-0199 to the patient in escalating doses, wherein the escalating doses comprise a dose of less than 300 mg per day followed by a dose of 300 mg per day.
39 . The method of claim 38 , wherein the method comprises administering the once daily dose of GDC-0199 in multiple dosing cycles.
40 . The method of claim 39 , wherein each dosing cycle of the multiple dosing cycles is 28 days.
41 . The method of claim 39 , wherein the GDC-0199 is administered in combination with an effective amount of obinutuzumab.
42 . The method of claim 41 , wherein each dosing cycle of the multiple dosing cycles is 28 days.
43 . The method of claim 42 , wherein the effective amount of the obinutuzumab is administered to the patient in combination with the GDC-0199 once in each dosing cycle for 6 to 7 dosing cycles.
44 . The method of claim 41 , wherein the effective amount of the obinutuzumab is 1000 mg.
45 . The method of claim 39 , wherein the GDC-0199 is administered in combination with an effective amount of dexamethasone.
46 . The method of claim 45 , wherein each dosing cycle of the multiple dosing cycles is 28 days.
47 . The method of claim 38 , wherein the multiple myeloma is refractory multiple myeloma.
48 . The method of claim 38 , wherein the method is continued until disease progression.
49 . A method for treating multiple myeloma in a human patient, the method comprising orally administering a once daily dose of GDC-0199 to the patient, wherein a starting dose of the once daily dose comprises 400 mg of GDC-0199.
50 . The method of claim 49 , wherein the method comprises administering the once daily dose of GDC-0199 in multiple dosing cycles.
51 . The method of claim 50 , wherein each dosing cycle of the multiple dosing cycles is 28 days.
52 . The method of claim 50 , wherein the GDC-0199 is administered in combination with an effective amount of obinutuzumab.
53 . The method of claim 52 , wherein each dosing cycle of the multiple dosing cycles is 28 days.
54 . The method of claim 53 , wherein the effective amount of the obinutuzumab is administered to the patient in combination with the GDC-0199 once in each dosing cycle for 6 to 7 dosing cycles.
55 . The method of claim 52 , wherein the effective amount of the obinutuzumab is 1000 mg.
56 . The method of claim 50 , wherein the GDC-0199 is administered in combination with an effective amount of dexamethasone, and wherein each dosing cycle of the multiple dosing cycles is 28 days.
57 . The method of claim 49 , wherein the multiple myeloma is refractory multiple myeloma.
58 . The method of claim 49 , wherein the method is continued until disease progression.
59 . The method of claim 49 , further comprising administering GDC-0199 to patient in escalating doses, wherein a starting dose of the escalating doses is less than 400 mg per day and an ending dose of the escalating doses is 400 mg per day.